1、Reducing Barriers:,Equity and Diversity in Clinical TrialsMichelle AudoinOICR PFAC,3CTN Patient Partner,CCTG Patient Representative,Who arethe experts in CT?Who are trials for?,Who I am,MomTeacherLiving with mBC and thyroid cancer,Who I am not,Academic researcherClinical trialistAny kind of medical
2、professional,My Journey:From Awareness,to Advocacy,To Action,2017 de novo mBC+thyroid cancer diagnosesResources and information about breast reconstruction for Black women?1st collaboration:Created Uncovered:A Breast Recognition ProjectRapid progression and failed treatments but no access to clinica
3、l trialsStarted to advocate for unmet needs for mBC and systemically underserved communities Systemic change is slow and I want to play an active roleAction plan:Attend conferencesBuild community and connections Engage with key stakeholders,Moving EDI Forward in Trials-3CTN Initiatives,4,Provided ex
4、pertise and strategic advice as a Person With Living Experience(PWLLE)Identified equitable best practices and practical resources with the EDI Working Group MembersShared my learnings with others,Michelle AudoinPFAC,Ontario Institute of Cancer Research,Anna JohnsonCanadian Cancer Trials Group,Roel S
5、chlijper-BosBC Cancer Prince George,Doreen EzeifeTom Baker Cancer Centre,Evani GollC17 Pediatric Council,Tina HsuUniversity of Ottawa,Holly LongstaffProvincial Health Services Authority,Laura McNab-CoombsBC Network Environment for Indigenous Health Research,Vinesha Ramasamy AYA CAN-Canadian Cancer A
6、dvocacy,EDI Working Group Members,3CTN EDI Framework and Resource Toolkit,5,Putting Best Practices to Practice,Building on 3CTNs early CRAFT(Canadian Remote Access Framework For Clinical Trials)successes and the recently launched EDI Framework3CTN to support p